Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2005 Nov;76(11):1472–1478. doi: 10.1136/jnnp.2004.035980

Present and future drug treatment for Parkinson's disease

A Schapira 1
PMCID: PMC1739397  PMID: 16227533

Abstract

Considerable advances made in defining the aetiology, pathogenesis, and pathology of Parkinson's disease (PD) have resulted in the development and rapid expansion of the pharmacopoeia available for treatment. Anticholinergics were used before the introduction of levodopa which is now the drug most commonly used. Dopamine agonists are effective when used alone or as an adjunct to levodopa, while monoamine oxidase B inhibitors improve motor function in early and advanced PD. However, treatment mainly addresses the dopaminergic features of the disease and leaves its progressive course unaffected; the drug treatment available for the management of non-motor symptoms is limited. This article seeks to set current treatment options in context, review emerging and novel drug treatments for PD, and assess the prospects for disease modification. Surgical therapies are not considered.

Full Text

The Full Text of this article is available as a PDF (97.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abdel-Aziz E., Arch B. N., Al-Taher H. The influence of religious beliefs on general practitioners' attitudes towards termination of pregnancy--a pilot study. J Obstet Gynaecol. 2004 Aug;24(5):557–561. doi: 10.1080/01443610410001722644. [DOI] [PubMed] [Google Scholar]
  2. Agid Y., Olanow C. W., Mizuno Y. Levodopa: why the controversy? Lancet. 2002 Aug 17;360(9332):575–575. doi: 10.1016/s0140-6736(02)09733-7. [DOI] [PubMed] [Google Scholar]
  3. Akao Yukihiro, Maruyama Wakako, Yi Hong, Shamoto-Nagai Masayo, Youdim Moussa B. H., Naoi Makoto. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett. 2002 Jun 28;326(2):105–108. doi: 10.1016/s0304-3940(02)00332-4. [DOI] [PubMed] [Google Scholar]
  4. Bar Am Orit, Amit Tamar, Youdim Moussa B. H. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett. 2004 Jan 30;355(3):169–172. doi: 10.1016/j.neulet.2003.10.067. [DOI] [PubMed] [Google Scholar]
  5. Basson R. Sex and idiopathic Parkinson's disease. Adv Neurol. 2001;86:295–300. [PubMed] [Google Scholar]
  6. Braak Heiko, Del Tredici Kelly, Rüb Udo, de Vos Rob A. I., Jansen Steur Ernst N. H., Braak Eva. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003 Mar-Apr;24(2):197–211. doi: 10.1016/s0197-4580(02)00065-9. [DOI] [PubMed] [Google Scholar]
  7. Brandt Thomas, Glasauer Stefan, Dieterich Marianne. Vestibular brainstem disorders: clinical syndromes in roll plane and their model simulation. Mov Disord. 2002;17 (Suppl 2):S58–S62. doi: 10.1002/mds.10061. [DOI] [PubMed] [Google Scholar]
  8. Carta Anna R., Pinna Annalisa, Tronci Elisabetta, Morelli Micaela. Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats. Neurology. 2003 Dec 9;61(11 Suppl 6):S39–S43. doi: 10.1212/01.wnl.0000095210.55600.9c. [DOI] [PubMed] [Google Scholar]
  9. Clarke C. E., Zobkiw R. M., Gullaksen E. Quality of life and care in Parkinson's disease. Br J Clin Pract. 1995 Nov-Dec;49(6):288–293. [PubMed] [Google Scholar]
  10. Clarke Carl E. Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease. Lancet Neurol. 2004 Aug;3(8):466–474. doi: 10.1016/S1474-4422(04)00823-3. [DOI] [PubMed] [Google Scholar]
  11. Colpaert F. C., Degryse A. D., Van Craenendonck H. V. Effects of an alpha 2 antagonist in a 20-year-old Java monkey with MPTP-induced parkinsonian signs. Brain Res Bull. 1991 Apr;26(4):627–631. doi: 10.1016/0361-9230(91)90106-t. [DOI] [PubMed] [Google Scholar]
  12. Corrigan M. H., Denahan A. Q., Wright C. E., Ragual R. J., Evans D. L. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety. 2000;11(2):58–65. doi: 10.1002/(sici)1520-6394(2000)11:2<58::aid-da2>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  13. Crosby N., Deane K. H., Clarke C. E. Amantadine in Parkinson's disease. Cochrane Database Syst Rev. 2003;(1):CD003468–CD003468. doi: 10.1002/14651858.CD003468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Dawson Ted M., Dawson Valina L. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 2003 Oct 31;302(5646):819–822. doi: 10.1126/science.1087753. [DOI] [PubMed] [Google Scholar]
  15. Del Tredici Kelly, Rüb Udo, De Vos Rob A. I., Bohl Jürgen R. E., Braak Heiko. Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol. 2002 May;61(5):413–426. doi: 10.1093/jnen/61.5.413. [DOI] [PubMed] [Google Scholar]
  16. Di Monte Donato A. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol. 2003 Sep;2(9):531–538. doi: 10.1016/s1474-4422(03)00501-5. [DOI] [PubMed] [Google Scholar]
  17. Durif F., Vidailhet M., Bonnet A. M., Blin J., Agid Y. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology. 1995 Oct;45(10):1855–1858. doi: 10.1212/wnl.45.10.1855. [DOI] [PubMed] [Google Scholar]
  18. Dziewczapolski G., Murer G., Agid Y., Gershanik O., Raisman-Vozari R. Absence of neurotoxicity of chronic L-DOPA in 6-hydroxydopamine-lesioned rats. Neuroreport. 1997 Mar 3;8(4):975–979. doi: 10.1097/00001756-199703030-00031. [DOI] [PubMed] [Google Scholar]
  19. Emre Murat, Aarsland Dag, Albanese Alberto, Byrne E. Jane, Deuschl Günther, De Deyn Peter P., Durif Franck, Kulisevsky Jaime, van Laar Teus, Lees Andrew. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004 Dec 9;351(24):2509–2518. doi: 10.1056/NEJMoa041470. [DOI] [PubMed] [Google Scholar]
  20. Fahn Stanley, Oakes David, Shoulson Ira, Kieburtz Karl, Rudolph Alice, Lang Anthony, Olanow C. Warren, Tanner Caroline, Marek Kenneth, Parkinson Study Group Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004 Dec 9;351(24):2498–2508. doi: 10.1056/NEJMoa033447. [DOI] [PubMed] [Google Scholar]
  21. Fernandez Hubert H., Trieschmann Martha E., Burke Monica A., Jacques Carol, Friedman Joseph H. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord. 2003 May;18(5):510–514. doi: 10.1002/mds.10374. [DOI] [PubMed] [Google Scholar]
  22. Ferrario Juan E., Taravini Irene R. E., Mourlevat Sophie, Stefano Andrea, Delfino Marina A., Raisman-Vozari Rita, Murer M. Gustavo, Ruberg Merle, Gershanik Oscar. Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system. J Neurochem. 2004 Sep;90(6):1348–1358. doi: 10.1111/j.1471-4159.2004.02595.x. [DOI] [PubMed] [Google Scholar]
  23. Gill Steven S., Patel Nikunj K., Hotton Gary R., O'Sullivan Karen, McCarter Renée, Bunnage Martin, Brooks David J., Svendsen Clive N., Heywood Peter. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003 Mar 31;9(5):589–595. doi: 10.1038/nm850. [DOI] [PubMed] [Google Scholar]
  24. Goetz C. G., Tanner C. M., Levy M., Wilson R. S., Garron D. C. Pain in Parkinson's disease. Mov Disord. 1986;1(1):45–49. doi: 10.1002/mds.870010106. [DOI] [PubMed] [Google Scholar]
  25. Gomez-Mancilla B., Bédard P. J. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol. 1993 Oct;16(5):418–427. doi: 10.1097/00002826-199310000-00004. [DOI] [PubMed] [Google Scholar]
  26. Gony Mireille, Lapeyre-Mestre Maryse, Montastruc Jean-Louis, French Network of Regional Pharmacovigilance Centers Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin Neuropharmacol. 2003 May-Jun;26(3):142–145. doi: 10.1097/00002826-200305000-00007. [DOI] [PubMed] [Google Scholar]
  27. Grondin R., Hadj Tahar A., Doan V. D., Ladure P., Bédard P. J. Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch Pharmacol. 2000 Feb;361(2):181–186. doi: 10.1007/s002109900167. [DOI] [PubMed] [Google Scholar]
  28. Grondin Richard, Zhang Zhiming, Yi Ai, Cass Wayne A., Maswood Navin, Andersen Anders H., Elsberry Dennis D., Klein Michael C., Gerhardt Greg A., Gash Don M. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain. 2002 Oct;125(Pt 10):2191–2201. doi: 10.1093/brain/awf234. [DOI] [PubMed] [Google Scholar]
  29. Gu Mei, Iravani M. M., Irvani M., Cooper J. Mark, King Diane, Jenner Peter, Schapira Anthony H. V. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J Neurochem. 2004 Dec;91(5):1075–1081. doi: 10.1111/j.1471-4159.2004.02804.x. [DOI] [PubMed] [Google Scholar]
  30. Halliwell B. Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke? Acta Neurol Scand Suppl. 1989;126:23–33. doi: 10.1111/j.1600-0404.1989.tb01779.x. [DOI] [PubMed] [Google Scholar]
  31. Happe S., Pirker W., Sauter C., Klösch G., Zeitlhofer J. Successful treatment of excessive daytime sleepiness in Parkinson's disease with modafinil. J Neurol. 2001 Jul;248(7):632–634. doi: 10.1007/s004150170148. [DOI] [PubMed] [Google Scholar]
  32. Hauber W., Neuscheler P., Nagel J., Müller C. E. Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats. Eur J Neurosci. 2001 Oct;14(8):1287–1293. doi: 10.1046/j.0953-816x.2001.01759.x. [DOI] [PubMed] [Google Scholar]
  33. Healy Daniel G., Abou-Sleiman Patrick M., Wood Nicholas W. PINK, PANK, or PARK? A clinicians' guide to familial parkinsonism. Lancet Neurol. 2004 Nov;3(11):652–662. doi: 10.1016/S1474-4422(04)00905-6. [DOI] [PubMed] [Google Scholar]
  34. Heikkinen H., Nutt J. G., LeWitt P. A., Koller W. C., Gordin A. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease. Clin Neuropharmacol. 2001 May-Jun;24(3):150–157. doi: 10.1097/00002826-200105000-00006. [DOI] [PubMed] [Google Scholar]
  35. Hely Mariese A., Morris John G. L., Reid Wayne G. J., Trafficante Robert. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005 Feb;20(2):190–199. doi: 10.1002/mds.20324. [DOI] [PubMed] [Google Scholar]
  36. Henry B., Fox S. H., Peggs D., Crossman A. R., Brotchie J. M. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord. 1999 Sep;14(5):744–753. doi: 10.1002/1531-8257(199909)14:5<744::aid-mds1006>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  37. Hillen M. E., Sage J. I. Nonmotor fluctuations in patients with Parkinson's disease. Neurology. 1996 Nov;47(5):1180–1183. doi: 10.1212/wnl.47.5.1180. [DOI] [PubMed] [Google Scholar]
  38. Hobson Douglas E., Lang Anthony E., Martin W. R. Wayne, Razmy Ajmal, Rivest Jean, Fleming Jonathan. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA. 2002 Jan 23;287(4):455–463. doi: 10.1001/jama.287.4.455. [DOI] [PubMed] [Google Scholar]
  39. Holloway Robert G., Shoulson Ira, Fahn Stanley, Kieburtz Karl, Lang Anthony, Marek Kenneth, McDermott Michael, Seibyl John, Weiner William, Musch Bruno. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004 Jul;61(7):1044–1053. doi: 10.1001/archneur.61.7.1044. [DOI] [PubMed] [Google Scholar]
  40. Hughes Andrew J., Daniel Susan E., Ben-Shlomo Yoav, Lees Andrew J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002 Apr;125(Pt 4):861–870. doi: 10.1093/brain/awf080. [DOI] [PubMed] [Google Scholar]
  41. Hussain I. F., Brady C. M., Swinn M. J., Mathias C. J., Fowler C. J. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2001 Sep;71(3):371–374. doi: 10.1136/jnnp.71.3.371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Ives Natalie J., Stowe Rebecca L., Marro Joanna, Counsell Carl, Macleod Angus, Clarke Carl E., Gray Richard, Wheatley Keith. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ. 2004 Aug 13;329(7466):593–593. doi: 10.1136/bmj.38184.606169.AE. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Jellinger K. A. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol. 1991 Jun;14(3):153–197. doi: 10.1007/BF03159935. [DOI] [PubMed] [Google Scholar]
  44. Jenner Peter. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Neurology. 2004 Oct 12;63(7 Suppl 2):S13–S22. doi: 10.1212/wnl.63.7_suppl_2.s13. [DOI] [PubMed] [Google Scholar]
  45. Kanda T., Jackson M. J., Smith L. A., Pearce R. K., Nakamura J., Kase H., Kuwana Y., Jenner P. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol. 1998 Apr;43(4):507–513. doi: 10.1002/ana.410430415. [DOI] [PubMed] [Google Scholar]
  46. Kanda T., Jackson M. J., Smith L. A., Pearce R. K., Nakamura J., Kase H., Kuwana Y., Jenner P. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol. 1998 Apr;43(4):507–513. doi: 10.1002/ana.410430415. [DOI] [PubMed] [Google Scholar]
  47. Kanda T., Jackson M. J., Smith L. A., Pearce R. K., Nakamura J., Kase H., Kuwana Y., Jenner P. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol. 2000 Apr;162(2):321–327. doi: 10.1006/exnr.2000.7350. [DOI] [PubMed] [Google Scholar]
  48. Kanda T., Jackson M. J., Smith L. A., Pearce R. K., Nakamura J., Kase H., Kuwana Y., Jenner P. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol. 2000 Apr;162(2):321–327. doi: 10.1006/exnr.2000.7350. [DOI] [PubMed] [Google Scholar]
  49. Karlsen K. H., Tandberg E., Arsland D., Larsen J. P. Health related quality of life in Parkinson's disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry. 2000 Nov;69(5):584–589. doi: 10.1136/jnnp.69.5.584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Katzenschlager R., Sampaio C., Costa J., Lees A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev. 2003;(2):CD003735–CD003735. doi: 10.1002/14651858.CD003735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Koga K., Kurokawa M., Ochi M., Nakamura J., Kuwana Y. Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur J Pharmacol. 2000 Nov 24;408(3):249–255. doi: 10.1016/s0014-2999(00)00745-7. [DOI] [PubMed] [Google Scholar]
  52. Kordower J. H., Emborg M. E., Bloch J., Ma S. Y., Chu Y., Leventhal L., McBride J., Chen E. Y., Palfi S., Roitberg B. Z. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science. 2000 Oct 27;290(5492):767–773. doi: 10.1126/science.290.5492.767. [DOI] [PubMed] [Google Scholar]
  53. Kostic V., Przedborski S., Flaster E., Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology. 1991 Feb;41(2 ):202–205. doi: 10.1212/wnl.41.2_part_1.202. [DOI] [PubMed] [Google Scholar]
  54. Lees A. J., Blackburn N. A., Campbell V. L. The nighttime problems of Parkinson's disease. Clin Neuropharmacol. 1988 Dec;11(6):512–519. doi: 10.1097/00002826-198812000-00004. [DOI] [PubMed] [Google Scholar]
  55. Mancini Francesca, Zangaglia Roberta, Cristina Silvano, Sommaruga Maria Grazia, Martignoni Emilia, Nappi Giuseppe, Pacchetti Claudio. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord. 2003 Jun;18(6):685–688. doi: 10.1002/mds.10420. [DOI] [PubMed] [Google Scholar]
  56. Marco Aimee Di, Appiah-Kubi Linda S., Chaudhuri K. Ray. Use of the dopamine agonist cabergoline in the treatment of movement disorders. Expert Opin Pharmacother. 2002 Oct;3(10):1481–1487. doi: 10.1517/14656566.3.10.1481. [DOI] [PubMed] [Google Scholar]
  57. Marsden C. D. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol. 1994;17 (Suppl 2):S32–S44. [PubMed] [Google Scholar]
  58. Maruyama W., Takahashi T., Youdim M., Naoi M. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm (Vienna) 2002 Apr;109(4):467–481. doi: 10.1007/s007020200038. [DOI] [PubMed] [Google Scholar]
  59. Murer M. G., Dziewczapolski G., Menalled L. B., García M. C., Agid Y., Gershanik O., Raisman-Vozari R. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol. 1998 May;43(5):561–575. doi: 10.1002/ana.410430504. [DOI] [PubMed] [Google Scholar]
  60. Nutt J. G., Burchiel K. J., Comella C. L., Jankovic J., Lang A. E., Laws E. R., Jr, Lozano A. M., Penn R. D., Simpson R. K., Jr, Stacy M. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003 Jan 14;60(1):69–73. doi: 10.1212/wnl.60.1.69. [DOI] [PubMed] [Google Scholar]
  61. Nutt J. G., Obeso J. A., Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci. 2000 Oct;23(10 Suppl):S109–S115. doi: 10.1016/s1471-1931(00)00029-x. [DOI] [PubMed] [Google Scholar]
  62. Nutt J. G., Woodward W. R., Beckner R. M., Stone C. K., Berggren K., Carter J. H., Gancher S. T., Hammerstad J. P., Gordin A. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 1994 May;44(5):913–919. doi: 10.1212/wnl.44.5.913. [DOI] [PubMed] [Google Scholar]
  63. O'Sullivan J. D. Apomorphine as an alternative to sildenafil in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2002 May;72(5):681–681. doi: 10.1136/jnnp.72.5.681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Obeso J. A., Olanow C. W., Nutt J. G. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 2000 Oct;23(10 Suppl):S2–S7. doi: 10.1016/s1471-1931(00)00031-8. [DOI] [PubMed] [Google Scholar]
  65. Ochi M., Koga K., Kurokawa M., Kase H., Nakamura J., Kuwana Y. Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience. 2000;100(1):53–62. doi: 10.1016/s0306-4522(00)00250-5. [DOI] [PubMed] [Google Scholar]
  66. Olanow C. W., Hauser R. A., Gauger L., Malapira T., Koller W., Hubble J., Bushenbark K., Lilienfeld D., Esterlitz J. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol. 1995 Nov;38(5):771–777. doi: 10.1002/ana.410380512. [DOI] [PubMed] [Google Scholar]
  67. Olanow C. Warren, Agid Yves, Mizuno Yoshi, Albanese Alberto, Bonuccelli Ubaldo, Bonucelli U., Damier Philip, De Yebenes Justo, Gershanik Oscar, Guttman Mark. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord. 2004 Sep;19(9):997–1005. doi: 10.1002/mds.20243. [DOI] [PubMed] [Google Scholar]
  68. Pact V., Giduz T. Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology. 1999 Sep 22;53(5):1154–1154. doi: 10.1212/wnl.53.5.1154-a. [DOI] [PubMed] [Google Scholar]
  69. Pardo B., Mena M. A., Casarejos M. J., Paíno C. L., De Yébenes J. G. Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants. Brain Res. 1995 Jun 5;682(1-2):133–143. doi: 10.1016/0006-8993(95)00341-m. [DOI] [PubMed] [Google Scholar]
  70. Paus Sebastian, Brecht Hans Michael, Köster Jürgen, Seeger Gert, Klockgether Thomas, Wüllner Ullrich. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord. 2003 Jun;18(6):659–667. doi: 10.1002/mds.10417. [DOI] [PubMed] [Google Scholar]
  71. Pinna A., Fenu S., Morelli M. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse. 2001 Mar 1;39(3):233–238. doi: 10.1002/1098-2396(20010301)39:3<233::AID-SYN1004>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  72. Pollak P., Tison F., Rascol O., Destée A., Péré J. J., Senard J. M., Durif F., Bourdeix I. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004 May;75(5):689–695. doi: 10.1136/jnnp.2003.029868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Ponsen Mirthe M., Stoffers Diederick, Booij Jan, van Eck-Smit Berthe L. F., Wolters Erik Ch, Berendse Henk W. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol. 2004 Aug;56(2):173–181. doi: 10.1002/ana.20160. [DOI] [PubMed] [Google Scholar]
  74. Rabey J. M., Sagi I., Huberman M., Melamed E., Korczyn A., Giladi N., Inzelberg R., Djaldetti R., Klein C., Berecz G. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol. 2000 Nov-Dec;23(6):324–330. doi: 10.1097/00002826-200011000-00005. [DOI] [PubMed] [Google Scholar]
  75. Raffaele R., Vecchio I., Giammusso B., Morgia G., Brunetto M. B., Rampello L. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. Eur Urol. 2002 Apr;41(4):382–386. doi: 10.1016/s0302-2838(02)00054-4. [DOI] [PubMed] [Google Scholar]
  76. Rajput A. H. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord. 2001 Oct;8(2):95–100. doi: 10.1016/s1353-8020(01)00023-2. [DOI] [PubMed] [Google Scholar]
  77. Rascol O., Brooks D. J., Korczyn A. D., De Deyn P. P., Clarke C. E., Lang A. E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000 May 18;342(20):1484–1491. doi: 10.1056/NEJM200005183422004. [DOI] [PubMed] [Google Scholar]
  78. Rascol Olivier. Monoamine oxidase inhibitors--is it time to up the TEMPO? Lancet Neurol. 2003 Mar;2(3):142–143. doi: 10.1016/s1474-4422(03)00318-1. [DOI] [PubMed] [Google Scholar]
  79. Rektorová I., Rektor I., Bares M., Dostál V., Ehler E., Fanfrdlová Z., Fiedler J., Klajblová H., Kulist'ák P., Ressner P. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol. 2003 Jul;10(4):399–406. doi: 10.1046/j.1468-1331.2003.00612.x. [DOI] [PubMed] [Google Scholar]
  80. Savola Juha-Matti, Hill Michael, Engstrom Mia, Merivuori Hannele, Wurster Siegfried, McGuire Steven G., Fox Susan H., Crossman Alan R., Brotchie Jonathan M. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord. 2003 Aug;18(8):872–883. doi: 10.1002/mds.10464. [DOI] [PubMed] [Google Scholar]
  81. Schapira Anthony H. V. Disease modification in Parkinson's disease. Lancet Neurol. 2004 Jun;3(6):362–368. doi: 10.1016/S1474-4422(04)00769-0. [DOI] [PubMed] [Google Scholar]
  82. Schapira Anthony H. V., Olanow C. Warren. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA. 2004 Jan 21;291(3):358–364. doi: 10.1001/jama.291.3.358. [DOI] [PubMed] [Google Scholar]
  83. Schapira Anthony H. V., Olanow C. Warren. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Ann Neurol. 2003;53 (Suppl 3):S149–S159. doi: 10.1002/ana.10514. [DOI] [PubMed] [Google Scholar]
  84. Schapira Anthony H. Excessive daytime sleepiness in Parkinson's disease. Neurology. 2004 Oct 26;63(8 Suppl 3):S24–S27. doi: 10.1212/wnl.63.8_suppl_3.s24. [DOI] [PubMed] [Google Scholar]
  85. Schenkman M., Wei Zhu C., Cutson T. M., Whetten-Goldstein K. Longitudinal evaluation of economic and physical impact of Parkinson's disease. Parkinsonism Relat Disord. 2001 Sep;8(1):41–50. doi: 10.1016/s1353-8020(00)00079-1. [DOI] [PubMed] [Google Scholar]
  86. Shiozaki S., Ichikawa S., Nakamura J., Kitamura S., Yamada K., Kuwana Y. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl) 1999 Nov;147(1):90–95. doi: 10.1007/s002130051146. [DOI] [PubMed] [Google Scholar]
  87. Shoulson Ira, Oakes David, Fahn Stanley, Lang Anthony, Langston J. William, LeWitt Peter, Olanow C. Warren, Penney John B., Tanner Caroline, Kieburtz Karl. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002 May;51(5):604–612. doi: 10.1002/ana.10191. [DOI] [PubMed] [Google Scholar]
  88. Shults Clifford W., Oakes David, Kieburtz Karl, Beal M. Flint, Haas Richard, Plumb Sandy, Juncos Jorge L., Nutt John, Shoulson Ira, Carter Julie. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002 Oct;59(10):1541–1550. doi: 10.1001/archneur.59.10.1541. [DOI] [PubMed] [Google Scholar]
  89. Stocchi F., Carbone A., Inghilleri M., Monge A., Ruggieri S., Berardelli A., Manfredi M. Urodynamic and neurophysiological evaluation in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry. 1997 May;62(5):507–511. doi: 10.1136/jnnp.62.5.507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Stocchi Fabrizio, Vacca Laura, Berardelli Alfredo, Onofrj Marco, Manfredi Mario, Ruggieri Stefano. Dual dopamine agonist treatment in Parkinson's disease. J Neurol. 2003 Jul;250(7):822–826. doi: 10.1007/s00415-003-1086-0. [DOI] [PubMed] [Google Scholar]
  91. Thomas A., Iacono D., Luciano A. L., Armellino K., Di Iorio A., Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004 Jan;75(1):141–143. [PMC free article] [PubMed] [Google Scholar]
  92. Van Camp Guy, Flamez Anja, Cosyns Bernard, Weytjens Caroline, Muyldermans Luc, Van Zandijcke Michel, De Sutter Johan, Santens Patrick, Decoodt Pierre, Moerman Christian. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet. 2004 Apr 10;363(9416):1179–1183. doi: 10.1016/S0140-6736(04)15945-X. [DOI] [PubMed] [Google Scholar]
  93. Walkinshaw G., Waters C. M. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. J Clin Invest. 1995 Jun;95(6):2458–2464. doi: 10.1172/JCI117946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Wardas J., Konieczny J., Lorenc-Koci E. SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse. 2001 Aug;41(2):160–171. doi: 10.1002/syn.1070. [DOI] [PubMed] [Google Scholar]
  95. Whone Alan L., Watts Ray L., Stoessl A. Jon, Davis Margaret, Reske Sven, Nahmias Claude, Lang Anthony E., Rascol Olivier, Ribeiro Maria J., Remy Philippe. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003 Jul;54(1):93–101. doi: 10.1002/ana.10609. [DOI] [PubMed] [Google Scholar]
  96. van Hilten B., Hoff J. I., Middelkoop H. A., van der Velde E. A., Kerkhof G. A., Wauquier A., Kamphuisen H. A., Roos R. A. Sleep disruption in Parkinson's disease. Assessment by continuous activity monitoring. Arch Neurol. 1994 Sep;51(9):922–928. doi: 10.1001/archneur.1994.00540210094018. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES